

[0206] 35. M. Hombreiro-Pérez, J. Siepman, C. Zinutti, A. Lamprecht, N. Ubrich, M. Hoffman, R. Bodmeier and P. Maincent, *Journal of Controlled Release*, 88, 413-428 (2003).

[0207] 36. J.-Y. Zhang, B. A. Doll, E. J. Beckman and J. O. Hollinger, *Tissue Engineering*, 9, 1143-1157 (2003).

[0208] 37. Chen X, et al. *J Orthop Res*. 2005; 23(4):816-23.

[0209] 38. Gogolewski S, Gorna K, Turner A S. *J Biomed Mater Res A*. 2006; 77A(4):802-10.

[0210] 39. Ambrose CG, et al. *Clin Orthop Relat Res*. 2003; 415:279-85.

We claim:

1. A biodegradable polyurethane scaffold, comprising at least one polyisocyanate, polyisocyanate prepolymer, or both; at least one polyester polyol; at least one catalyst; wherein the density of said scaffold is from about 50 to about 250 kg m<sup>-3</sup> and the porosity of the scaffold is greater than about 70 (vol %) and at least 50% of the pores are interconnected with another pore; and wherein the scaffold incorporates at least one biologically active component in powder form.
2. The scaffold of claim 1, wherein the biologically active component has a hydroxyl or amine group.
3. The scaffold of claim 1, wherein the biologically active component is chosen from antibiotics, proteins, anti-cancer agents.
4. The scaffold of claim 1, wherein the biologically active component is an antibiotic.
5. The scaffold of claim 1, wherein the biologically active component is in powder form and chosen from tobramycin, colistin, tigecycline, BSA, PDGF, BMP-2.
6. The scaffold of claim 4, wherein the antibiotic is a labile tobramycin powder.
7. The scaffold of claim 1, wherein the polyisocyanate is an aliphatic polyisocyanates chosen from lysine methyl ester diisocyanate (LDI), lysine triisocyanate (LTI), 1,4-diisocyanatobutane (BDI), and hexamethylene diisocyanate (HDI), and dimers and trimers of HDI.
8. The scaffold of claim 1, wherein the density is at least about 90 kg m<sup>-3</sup>.
9. The scaffold of claim 1, further comprising an excipient in a range of 5 about wt % or less, or in a range of from about 0.5 wt % to about 4 wt %.
10. The polyurethane scaffold of claim 1, further comprising PEG.
11. The polyurethane scaffold of claim 10, wherein the PEG is present in an amount of about 50% or less w/w or in an amount of about 30% or less w/w.
12. The scaffold of claim 1, wherein the porosity is greater than 70 (vol-%), or the porosity is from about 90 to about 95 (vol-%).
13. The scaffold of claim 1, further comprising a stabilizer chosen from a polyethersiloxane, sulfonated castor oil, and sodium ricinoleicsulfonate.
14. The scaffold of claim 1, further comprising a second biologically active agent.
15. The scaffold of claim 14, wherein the second biologically active agent comprises demineralized bone particles.
16. The scaffold of claim 1, wherein the second biologically active agent is chosen from enzymes, organic catalysts, ribozymes, organometallics, proteins, glycoproteins, peptides, polyamino acids, antibodies, nucleic acids, steroidal molecules, antibiotics, antivirals, antimycotics, anticancer agents, analgesic agents, antirejection agents, immunosup-

pressants, cytokines, carbohydrates, oleophobic, lipids, extracellular matrix and/or its individual components, demineralized bone matrix, pharmaceuticals, chemotherapeutics, cells, viruses, virenos, virus vectors, and prions,

17. The scaffold of claim 1, wherein the biologically active agent is an antibiotic, and is present in an amount of from about 1-12 wt %.

18. The scaffold of claim 17, wherein the biologically active agent is present in an amount of from about 2 to about 10 wt %; or the biologically active agent is present in an amount of from 4 to about 10 wt %.

19. The scaffold of claim 1, wherein the biologically active agent is a protein, and is present in an amount of from about 0.01 to about 10000 µg/ml of scaffold; or in an amount from about 0.1 to about 5000 µg/ml of scaffold; or in an amount from about 1 to about 5000 µg/ml of scaffold.

20. A composition that comprises: at least one polyisocyanate, polyisocyanate prepolymer, or both; at least one polyester polyol; at least one catalyst; and at least one biologically active component in powder form.

21. The composition of claim 20, wherein the biologically active component is chosen from antibiotics, proteins, anti-cancer agents.

22. The composition of claim 21, wherein the biologically active component is an antibiotic incorporated in powdered form.

23. The composition of claim 22, wherein the biologically active agent is a protein, and is present in an amount of from about 0.01 to about 1000 µg/ml of scaffold; or in an amount from about 0.1 to about 5000 µg/ml of scaffold; or in an amount from about 1 to about 5000 µg/ml of scaffold.

24. The composition of claim 22, wherein the antibiotic is a labile tobramycin powder.

25. The composition of claim 20, further comprising an excipient in a range of 5 about wt % or less, or in a range of from about 0.5 wt % to about 4 wt %.

26. The composition of claim 20, further comprising a PEG in an amount of about 50% or less w/w or in an amount of about 30% or less w/w.

27. The composition of claim 20, further comprising a stabilizer chosen from a polyethersiloxane, sulfonated castor oil, and sodium ricinoleicsulfonate.

28. The composition of claim 20, wherein the biologically active agent is incorporated as a powder and is present in an amount of from about 2 to about 10 wt or the biologically active agent is present in an amount of from 4 to about 10 wt %.

29. The composition of claim 20, wherein the polyisocyanate is an aliphatic polyisocyanates chosen from lysine methyl ester diisocyanate (LDI), lysine triisocyanate (LTI), 1,4-diisocyanatobutane (BDI), and hexamethylene diisocyanate (HDI), and dimers and trimers of HDI.

30. A method of delivering a biologically active agent to a wound site, comprising:

providing a composition that comprises at least one polyisocyanate, polyisocyanate prepolymer, or both; at least one polyester polyol; at least one catalyst; and at least one biologically active component in powder form; and contacting the composition with a wound site.

31. The method of claim 30, wherein the wound site is a bone.

32. The method of claim 30, wherein the wound site is skin.

\* \* \* \* \*